Luo Z.-L.,General Surgery Center |
Chen L.-G.,The 452 Hospital of PLA |
Miao J.-G.,General Surgery Center |
Yan H.-T.,General Surgery Center |
And 2 more authors.
Chinese Journal of Evidence-Based Medicine | Year: 2011
Objective To evaluate the clinical application value of the tauro ursodeoxycholic acid (TUDCA) for preventing the relapse of lithiasis afer the gallbladder-protected lithotomy. Methods Totally 80 cholecyslithiasis patients in Chengdu General Military Hospital who met the demand of lithotomy in protecting gallbladder were divided into two groups by random permutations, with 40 patients in each. Te calculus was removed by using the percutaneous ultrasonic lithotripsy in order to preserve the well-functioning gallbladder. Te patients in the trial group were given TUDCA after surgery for two years, whereas the patients in the control group received the same nursing and diet therapies without medication. Te thickness of gallbladder wall and the contraction function of gallbladder were checked two years after surgery, the statistics of the recurrence rate of liary calculus symptoms and cholecyslithiasis were conducted, and the comparison between those two groups was performed. Results All the operations of gallbladder-protected lithotomy were successful. There was significant difference between those two groups two years after surgery in terms of the thickness of gallbladder wall and the contraction function of gallbladder (P<0.05). Te relapse of lithiasis was remarkably decreased in the trial group (P<0.05). Conclusion Te application of TUDCA for patients with gallbladder-protected lithotomy can prevent the relapse of cholecyslithiasis. © 2011 Editorial Board of Chin J Evid-based Med. Source
Huang M.,The 452 Hospital of PLA |
Feng Z.,The 452 Hospital of PLA |
Ji D.,The 452 Hospital of PLA |
Cao Y.,The 452 Hospital of PLA |
And 5 more authors.
Cytotherapy | Year: 2014
Background aims: Currently, there is no treatment for decompensated liver cirrhosis except for liver transplantation. The safety and effect on liver function of a transjugular intrahepatic portosystemic shunt (TIPS) with and without autologous bone marrow cell (BMC) infusion in patients with decompensated liver cirrhosis were determined. Methods: Ten patients who were diagnosed with decompensated liver cirrhosis during the period from September 2011 to July 2012 were enrolled in this study. The patients underwent TIPS (TIPS group) or combined treatment with TIPS and BMC infusion through the hepatic artery (TIPS+BMC group). All patients were monitored for adverse events, liver function and complications caused by portal hypertension during a period of 52 weeks. Results: The number of infused BMCs was 2.65 ± 1.20×109. Significant improvements in the serum levels of albumin and total bilirubin and decreased Child-Pugh scores were observed in patients treated with both TIPS and BMCs (P< 0.05), whereas no such changes were observed in the TIPS group. Endoscopic findings showed that varices in the esophagus and the gastric fundus were alleviated after either treatment. All 10 patients showed a complete or partial resolution of ascites at 4 weeks. No major adverse effects were noted during the follow-up period for patients in either group. Conclusions: TIPS combined with BMC infusion is clinically safe; the treatment improved liver function and alleviated complications caused by portal hypertension; therefore, this combination has potential for treatment of patients with decompensated liver cirrhosis. © 2014 International Society for Cellular Therapy. Source